|
|
 |
|
Viewing report
|
|
|
|
Thought Leader Insight & Analysis: Alzheimer's Disease
Medpredict, Jan 2008
This report focuses on a variety of clinical approaches and diagnostics targeting either cognition or disease progression in Alzheimer’s disease. The report, #14 in the series, is based on seven interviews conducted with a cohort of national US peer-recognized AD experts. As 2008 begins the publisher’s Panelists were asked to review major developments this past year and to forecast the changes they expect to see in the Alzheimer’s competitive landscape in 2008. Each Panelist offers his perspective on those agents and mechanisms that have the strongest data supporting them, and comments on those where the excitement extends beyond the clinical evidence. These include acetylcholinesterase (butyrylcholinesterase) inhibitors, NMDA, M1, 5-HT, alpha-7 nicotinic acetylcholine agonists, active and passive immunotherapy, ?-secretase and ß-secretase inhibitors, insulin related mechanisms (IDE, RAGE), plasminogen activator inhibitor-1, anti-TNF, GSK3 and more. Given the size of the patient population and the lack of approved therapeutics that provide long-term disease control it is no surprise how many competitors are trying to commercialize drugs for this market. This in addition to the drugs highlighted as most interesting by the Panel the publisher offers in this report a program guide of new compounds, reflecting the many “shots on goal”. The publisher does this with the caveat that just because they name them doesn’t mean that they endorse them. The AD field is strewn with the bones of much hyped new chemical entities that did not stand up to closer scrutiny. But, they do provide a starting point for future Panel discussions.
Customers who bought this item also bought
Wyeth
Alzheimer Disease - New Drugs, Markets and Companies
Central Nervous System Alzheimer Disease
Alzheimer�s Disease - Drug Pipeline Analysis and Market Forecasts to 2015
Bapineuzumab Phase 2 Clinical Trial Results Call - Wyeth,Elan Corp. Plc, - Earnings Transcript
Bapineuzumab Phase 2 Clinical Trial Results Call - Wyeth,Elan Corp. Plc, - Earnings Transcript
Central Nervous System - Alzheimer Disease Drug Pipeline Report
Emerging Drug Targets in Alzheimer's Disease
Acquisition of Wyeth by Pfizer, Inc Call - - Earnings Transcript
Acquisition of Wyeth by Pfizer, Inc Call - - Earnings Transcript
Small Molecule Kinase Inhibitors - Global Strategic Business Report
CNS Drug Discoveries: Alzheimer's Disease Chapter
|
|
|
|
